daily semaglutide FDA Approves Oral Semaglutide: First GLP-1 Weight Loss Pill Semaglutide for Weight Loss Management

The pivotal trial supporting its 2010 FDA approval enrolled 816 HIV-infected adults with clinically defined lipodystrophy, and Phase 3 data documented visceral fat reductions of roughly 15-18% over 26 weeks of treatment a result robust enough to clear FDA review for a defined medical indication

Recent analyses presented at the National Lipid Associations 2025 Scientific Sessions highlighted cardiovascular, renal, and metabolic gains from GLP1s that appear partly independent of the amount of weight loss

At least a 50% reduction in eGFR from baseline

Produces a depletion of releasable neuronal monoamine neurotransmitters Similar mechanism as tetrabenazine (Austedo )

Baseline urine glucose assessment and periodic follow-up help quantify glycosuria exposure

Gastrointestinal issues : Persistent nausea, vomiting, and diarrhea have been linked to the use of these medications